Further investigation will be required to evaluate the potential clinical application of LDN to post-COVID-19 condition patients such as assessing TRPM3 ion channel activity in NK cells from patients taking LDN, and clinical trials to confirm the benefit of LDN in improving QoL of post-COVID-19 condition patients. The gene discussed is TRPM3; the disease is COVID-19.